Evusheld Appears Less Effective Against Omicron for Patients With Blood Cancer
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
Leukemia
Blinatumomab Linked to Higher Costs, Hospitalizations for R/R ALL
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
Quizartinib Improves Overall Survival in FLT3-ITD+ Acute Myeloid Leukemia
Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.
Fixed Combination Decitabine/Cedazuridine Plus Venetoclax Feasible in Acute Myeloid Leukemia
Researchers sought to determine whether ASTX727 with venetoclax would be effective in patients with AML.
Study: Nearly One-Third of Children With Hematologic Cancers Develop Cardiotoxicity
All patients with cardiotoxicity recovered within 2 months.
Two-Step Strategy Promising in TKI Dose Reduction in Chronic Myeloid Leukemia
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
Momelotinib May Improve Some Outcomes Vs Danazol in Myelofibrosis
Researchers sought to determine whether momelotinib would improve outcomes in patients with anemic myelofibrosis compared with danazol.
TP53 Mutations Predict Poor Outcomes in Patients With MDS or AML With Complex Karyotype
Researchers sought to determine whether TP53 mutations would be linked with more aggressive disease in patients with MDS or AML.
Researchers Identify RAD21 Variants in Pediatric Lymphoblastic Leukemia or Lymphoma
Researchers sought to determine the relevance of the RAD21 gene in pediatric lymphoblastic leukemia or lymphoma.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...